APAC to record fastest-growing interventional oncology market | Health Care Asia Magazine

APAC to record fastest-growing interventional oncology market

There has been an expanding research base across India, China, and Japan.

Asia Pacific is set to have the fastest-growing interventional oncology market worldwide, driven by government efforts to ramp up funding and supportive regulations for the development and commercialization of such products, according to a report from Research and Markets.

Also spurring growth in the market are rising healthcare expenditure, a growing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the rising incidence of surgeries.

Globally, the interventional oncology market size is projected to reach $2.9b by 2026 from $1.9b in 2020, at a compound annual growth rate (CAGR) of 6.8%, propelled by factors such as the technological advancements in the market.

Additionally, rising cases of surgeries, investments from both private and public sectors are having effects on the market’s growth. However, it is held back by unfavorable reimbursement scenarios in some countries.

Demand from the main end-users has declined as key regions and countries have imposed social distancing rules and lockdowns. However, this impact is expected to be short-term, and no adverse effects are sighted in the future after the market gradually reopens

Get Health Care Asia Magazine in your inbox
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The majority of the country’s pharma manufacturing produces generic drugs.
This is expected to affect local pharma growth in the short term.
Nonetheless, more than half of the age group found its use to be comfortable.
The group’s profits after tax ballooned by as much as 138.4%.
Funds will be used to build out its behavioural health and chronic care modules.
Some players have been highly active in digital channels of various countries.
It has also formed a JV with Acurio to develop a private hospital in NSW.
With this, the company now offers an all-in-one patient management service.
The therapy can be done in eight different languages.
The country is expected to have one in five of its population to be elderly by 2050.
Sunway is planning to ramp up its hospital capacity to about 3,000 beds.
The system will help city managers to track epidemic conditions, real-time.
It is funded through the 2020 Primary Healthcare Research Data Infrastructure grants.
The hospital features 200 general inpatient beds and 100 hemodialysis beds.
The platform expanded its services after obtaining an internet hospital license.